Clinical Trials Logo

Acute Renal Failure clinical trials

View clinical trials related to Acute Renal Failure.

Filter by:

NCT ID: NCT00076219 Completed - Acute Renal Failure Clinical Trials

Acute Renal Failure Trial Network (ATN) Study

ATN
Start date: October 2003
Phase: Phase 3
Study type: Interventional

This is a multi-center, prospective, randomized, parallel-group trial of an intensive strategy vs conventional strategy of renal replacement therapy for the treatment of acute renal failure secondary to acute tubular necrosis in critically ill patients. The primary hypothesis is that the intensive strategy will reduce 60-day all cause mortality by 10% compared to the conventional strategy - i.e.,a reduction from 55% in the conventional arm to 45% in the intensive arm. Secondary outcomes are 60-day in-hospital all-cause mortality, 1-year all cause mortality, and recovery of renal function by day 28. The study will recruit 1164 patients over a period of 3 years, 8 months and each patient will be actively followed for 60 days.

NCT ID: NCT00004496 Completed - Acute Renal Failure Clinical Trials

Phase I Study of Alpha-Melanocyte Stimulating Hormone in Patients With Acute Renal Failure

Start date: February 1999
Phase: Phase 1
Study type: Interventional

OBJECTIVES: I. Determine the maximum tolerated dose and safety of alpha-melanocyte stimulating hormone (alpha-MSH) in patients with acute renal failure. II. Determine the safety and pharmacokinetics of alpha-MSH in patients at high risk of acute renal failure after renal transplantation. III. Determine the safety and pharmacokinetics of alpha-MSH in patients with established ischemic acute renal failure. IV. Determine the effect of alpha-MSH on interleukin-10 pharmacokinetics.